Navigation Links
AEterna Zentaris to Present at Upcoming Rodman & Renshaw Global Healthcare Conference and AUA Annual Meeting
Date:5/15/2008

QUEBEC CITY, May 15 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its Senior Vice President and Chief Financial Officer, Dennis Turpin, CA, will present a company overview at the upcoming Rodman & Renshaw 5th Annual Global Healthcare Conference on Tuesday, May 20, 2008 at 9:40 am (local time), in the Atlantique Salon - Meridional (2nd floor) of the Meridien Beach Plaza Hotel at the Sea Club, in Monaco.

A live webcast of this presentation will be available on AEterna Zentaris' website at http://www.aezsinc.com in the Investors section. A replay will also be available for a period of 30 days on the Company's website.

Also on Tuesday, May 20, 2008, Professor, Jurgen Engel, Ph.D., Executive Vice President and Chief Scientific Officer at AEterna Zentaris will make a poster presentation at the American Urological Association's Annual Meeting, from 10:30 am to 12:30 pm (Eastern Time) in Room 315 AB of the Orange County Convention Center in Orlando, Florida. Titled, "Luteinizing Hormone-Releasing Hormone (LHRH) Receptors in BPH as Potential Molecular Targets for Therapy with Cetrorelix", the presentation will focus on the Company's lead compound, cetrorelix, which could provide rapid and long lasting improvement of symptoms in men with benign prostatic hyperplasia.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal
2. AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results
3. AEterna Zentaris to Announce First Quarter 2008 Financial and Operating Results and Hold Annual Shareholder Meeting on May 7, 2008
4. AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan
5. AEterna Zentaris Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia
6. AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia
7. AEterna Zentaris Announces Changes to its Management Team
8. AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights
9. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... San Mateo, CA (PRWEB) July 14, 2014 ... groundbreaking CONNECT patient registry platform, announced that ... Becker muscular dystrophies; the Phelan-McDermid Syndrome International ... primary Nephrotic Syndrome—have been awarded contracts by ... part of the creation of a new ...
(Date:7/13/2014)... -- The discovery 30 years ago of soccer-ball-shaped carbon ... nanotechnology research. Now, there appears to be a new ... Shanxi University and Tsinghua University in China have shown ... hollow molecular cage similar to a carbon buckyball. It,s ... only a matter of speculationdoes indeed exist. , "This ...
(Date:7/13/2014)... 2014 Deep Research Report on Global and China ... on the current state of the Nano Silver industry ... basic overview of the industry, including definitions, applications and ... market analysis are provided with a focus on history, ... comparison between the international and Chinese situation is also ...
(Date:7/12/2014)... York (PRWEB) July 12, 2014 ... for various reagents used in the life ... driving the life science reagents market towards ... include manufacturers and providers of life science ... Market Report: http://www.transparencymarketresearch.com/life-sciences-reagents-analytical-reagents.html . , The ...
Breaking Biology Technology:PatientCrossroads Fuels Development of New National Clinical Research Network 2PatientCrossroads Fuels Development of New National Clinical Research Network 3Researchers discover boron 'buckyball' 2Researchers discover boron 'buckyball' 32014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 22014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 3Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3
... - Appointment Enhances Algeta,s Commercial Capabilities ... Cancer , Algeta ASA ... Kay has been appointed as President and Chief,Executive Officer and ... Thomas,Ramdahl will continue as Executive Vice President and Chief Technology,Officer ...
... TUSTIN, Calif., Dec. 11 Peregrine Pharmaceuticals, Inc. (Nasdaq: ... its Board of Directors, unexpectedly passed away on Wednesday. Dr. ... chairman since 2005. At the time of his death, Dr. ... , , "The sudden ...
... Alimera Sciences Inc., a privately held,biopharmaceutical company ... prescription ophthalmic pharmaceuticals, today reported,that enrollment has begun ... and efficacy,of Iluvien(TM) in patients with bilateral geographic ... The pilot ...
Cached Biology Technology:Algeta Appoints Andrew Kay as President and Chief Executive Officer 2Algeta Appoints Andrew Kay as President and Chief Executive Officer 3Algeta Appoints Andrew Kay as President and Chief Executive Officer 4Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz 2Alimera Sciences Begins Pilot Study to Assess Safety and Efficacy of Iluvien(TM) in Patients With Bilateral Geographic Atrophy Due to AMD 2
(Date:7/11/2014)... that cannabinoid receptor type 1 can inhibit ... and reduce neurotransmitter release. However, some scholars ... increase extracellular Ca2+ influx and increase neurotransmitter ... Tongji Hospital Affiliated to Tongji Medical College, ... used whole cell voltage-clamp and calcium imaging ...
(Date:7/11/2014)... of all vertebrates, information is transmitted through synapses, ... signal to be passed from one brain cell ... abundant type of synapse, can be either excitatory ... memory, perception and cognition, and the balance between ... For instance, every time we learn something, ...
(Date:7/10/2014)... NEW YORK , June 27, 2014 /PRNewswire/ ... against Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: ... action, filed in United States District Court, Middle ... Division, is on behalf of a class consisting ... otherwise acquired Provectus securities between December 17, 2013 ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
... shellfish, snails and other animals from the Pacific Ocean ... was interrupted by cooling conditions three million years ago, ... of California, Davis, and Peter Roopnarine at the California ... ice-free Arctic Ocean by 2050. That will restore conditions ...
... Pharmacy researchers have discovered a marine compound off the ... in laboratory tests, a finding they hope will fuel ... disease. The UF-patented compound, largazole, is derived from ... results from early studies today (Aug. 7) at an ...
... The University of Houston department of health and human performance ... a study promoting healthy dietary habits and physical activity. ... of Second Life (SL). , ... is part of the UH Texas Obesity Research Center,s (TORC) ...
Cached Biology News:Pacific shellfish ready to invade Atlantic 2Researchers find cancer-inhibiting compound under the sea 2Researchers find cancer-inhibiting compound under the sea 3TORC at UH turns to virtual world of Second Life for new study 2
XEDAR Antibody...
Xanthine Oxidase (Bovine Buttermilk). Monospecific by IEP. Some cross reactivity with Xanthine Oxidase of other species and tissues may occur....
Rabbit Anti-JNK1/SAPK pan, Polyclonal Antibody...
...
Biology Products: